←
John Kellum544 posts
John Kellum avatar

John Kellum

@kellumja
◷ Joined September 2014▧ 32 Photos and videos
John Kellum avatar
John Kellum@kellumja·Jul 26

Do Microshit developers actually use their own products? Several updates ago (probably like 50 since they update ever 3 or 4 days) the made it so when you read a comment and then scroll down it will force you back to comment so that you lose your place in the doc thx @Microsoft !

John Kellum avatar
John Kellum@kellumja·15 Oct 2025

TIMP-2 and IGFBP7 are stress markers for the kidney, no stress, no protection. Now the stage is set to do a large trial of RIPC using sevoflurane anesthesia and better yet we can also titrate RIPC to biomarker response. Precision medicine at its finest!

John Kellum avatar
John Kellum@kellumja·15 Oct 2025

...It turns out that the big trials used propofol and there is body of evidence showing that this agent blocks the protective effect of RIPC. Now with this paper we show how. Propofol interferes with the release of TIMP-2 and IGFBP7 from the kidney in response to RIPC...

John Kellum avatar
John Kellum@kellumja·15 Oct 2025

Impact of propofol or sevoflurane on the renoprotective effect of remo... sciencedirect.com/science/ar… --This is a fascinating story. RIPC seems to work in some trials but not at all in others. Two big trials were negative so that's the end of story right? Not so fast. . .

John Kellum avatar
John Kellum@kellumja·11 Oct 2025

Funny thing. . . 7% of patients with sepsis have "Nephrons of Steel" and don't develop Acute Kidney Injury when by all accounts they should. These "AKI-resistant" humans may hold the key to AKI prevention and therapy. doi.org/10.1186/s13054-025-0…

John Kellum avatar
John Kellum@kellumja·12 Aug 2025

After more than 5 years and nearly 15,000 patients screened, main results from Tigris are out! Precision medicine isn’t for the faint of heart! PMX Hemoadsorption to remove endotoxin is highly effective in this very select population globenewswire.com/news-relea…

John Kellum avatar
John Kellum@kellumja·26 Mar 2025

As seen in other studies, about half of all patients admitted to the ICU develop AKI with about 2/3 stage 2-3. However only 12% of stage 2-3 are have persistent severe kidney dysfunction. Outcomes for these pts are far worse. Endpoint for drug trials? rdcu.be/eebnP

John Kellum avatar
John Kellum@kellumja·20 Mar 2025

Check out table 4. AKI rates were not different across study arms with the exception of DAPA-HF trial in which serious kidney events were actually less common with dapagliflozin compared to placebo (P=0.009). The claim that SGLT2 inhibitors cause AKI is demonstrably FALSE.

John Kellum avatar
John Kellum@kellumja·20 Mar 2025

The authors cite the 2019 CREDENCE trial for this claim but there was no difference in the rates of AKI between canagliflozin (1.69%) and placebo (2.0%) reported in the trial...